Results 111 to 120 of about 14,945 (175)

Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β Blockade

JACC: Advances
Background: Serum urate (SU) associates with cardiovascular (CV) events, mortality, and gout. Objectives: The purpose of this study was to assess whether SU predicts CV risk in a trial of interleukin (IL)-1β inhibition with canakinumab, and whether IL-1β
Nicholas H. Adamstein, MD, Jean G. MacFadyen, BA, Brittany N. Weber, MD, PhD, Peter Libby, MD, Daniel H. Solomon, MD, MPH, Paul M Ridker, MD, MPH   +5 more
doaj   +1 more source

Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. [PDF]

, 2015
BACKGROUND: To investigate potential cardiovascular and other effects of long-term pharmacological interleukin 1 (IL-1) inhibition, we studied genetic variants that produce inhibition of IL-1, a master regulator of inflammation.
Interleukin 1 Genetics Consortium
core  

Canakinumab: un anticuerpo monoclonal prometedor en el tratamiento de enfermedades cardiovasculares Canakinumab: a promising monoclonal antibody in the treatment of cardiovascular diseases

Revista Colombiana de Cardiología, 2013
El canakinumab es un anticuerpo monoclonal anti-IL-1β totalmente humano desarrollado por Novartis, cuyo mecanismo de acción se basa en la neutralización de la señalización IL-1β, lo cual conduce a la supresión de la inflamación en pacientes con
Fernando Manzur, Carlos Moneriz
doaj  

Evaluation of the Effect of IL-1 Antagonists on Pituitary Function. [PDF]

Int J Endocrinol
Aktas Koc F, Sariakcali B, Sahin A.
europepmc   +1 more source

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS) [PDF]

, 2017

core   +1 more source

Three-year follow-up of canakinumab dose extension in children with colchicine-resistant familial Mediterranean fever: PeRA-RG Experience. [PDF]

Rheumatology (Oxford)
Kavrul Kayaalp G, Çağlayan Ş, Ulu K, Türkmen Ş, Demirkan FG, Guliyeva V, Otar Yener G, Öztürk K, Demir F, Özdel S, Çakan M, Sönmez HE, Sözeri B, Aktay Ayaz N, PeRA Research Group .   +14 more
europepmc   +1 more source

Evaluation of the real-world safety of Canakinumab in the treatment of systemic juvenile idiopathic arthritis in children aged 0-16: a comprehensive analysis based on FAERS data. [PDF]

Pediatr Rheumatol Online J
Xiao P, Wei B, Zhang G, Zhang X, Wan H, Qi Y, Chen L, Huang Y, Liu J.   +8 more
europepmc   +1 more source

Inflammatory osteolysis: A conspiracy against bone [PDF]

, 2017
Abu-Amer, Abu-Amer, Anton, Bardin, Beranger, Chen, Christo, Claro, Cobelli, Coll, Dapunt, Deborah V. Novack, Dewhirst, Gabriel Mbalaviele, Georg Schett, Gravallese, Harre, Josse, Jovanovic, Kollias, Lukens, Maitra, McCall, Mukai, Negishi-Koga, Osta, Ozen, Pasco, Robaszkiewicz, Rubbert-Roth, Sanchez, Scianaro, Sharma, Steven L. Teitelbaum, Van Hauwermeiren, Wang, Zaki   +36 more
core   +2 more sources

Disproportionality Analysis of Adverse Events Associated with IL-1 Inhibitors in the FDA Adverse Event Reporting System (FAERS). [PDF]

Pharmaceuticals (Basel)
Lei J, Lou Z, Jiang Y, Cui Y, Li S, Hu J, Jing Y, Yang J.   +7 more
europepmc   +1 more source

Pregnancy outcomes after maternal and paternal anti-IL-1 treatment exposure in cryopyrin-associated periodic syndromes (CAPS). [PDF]

Rheumatology (Oxford)
Satirer Ö, Henes J, Henes M, Benseler SM, Kuemmerle-Deschner JB.   +4 more
europepmc   +1 more source